Logo

UCB's Cimzia (certolizumab pegol) Receives Health Canada Approval for Non-Radiographic Axial Spondyloarthritis

Share this

UCB's Cimzia (certolizumab pegol) Receives Health Canada Approval for Non-Radiographic Axial Spondyloarthritis

Shots:

  • The approval is based on P-III C-AXSPAND study assessing Cimzia (400mg) vs PBO + common background medications in 317 patients with severe active nr-axSpA with an objective sign of inflammation as indicated by elevated CRP/ MRI evidence who had an inadequate response to/ or intolerant to NSAIDs
  • The P-III C-AXSPAND study results: met its 1EPs & 2EPs i.e- improvement in ASDAS-MI @52wks. (47.2% vs 7.0%) & improvement in ASAS40 @12wks. (47.8% vs 11.4%)
  • Cimzia is the only Fc-free- PEGylated anti-TNF- having high affinity for human TNF-alpha and is indicated for reducing signs and symptoms in adult patients with active AS. The approval marks the fifth indication for Cimzia

Click here ­to­ read full press release/ article | Ref: Newswire Canada | Image: StraitTimes


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions